Leerink Partnrs Estimates Biogen’s Q3 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for Biogen in a research report issued on Thursday, July 31st. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings per share of $3.86 for the quarter, down from their prior forecast of $4.04. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen’s FY2026 earnings at $16.00 EPS and FY2027 earnings at $16.40 EPS.

Several other equities analysts have also commented on BIIB. Needham & Company LLC restated a “hold” rating on shares of Biogen in a research note on Thursday, June 12th. HSBC lowered Biogen from a “buy” rating to a “hold” rating and set a $118.00 price target on the stock. in a research note on Monday, April 28th. Canaccord Genuity Group dropped their price objective on shares of Biogen from $265.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Citigroup increased their price objective on shares of Biogen from $125.00 to $135.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Oppenheimer set a $205.00 price objective on shares of Biogen in a research note on Friday, May 2nd. Twenty-one analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Biogen has a consensus rating of “Hold” and an average target price of $185.63.

Biogen Stock Performance

BIIB stock opened at $131.95 on Monday. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. The business’s fifty day simple moving average is $129.84 and its two-hundred day simple moving average is $131.69. Biogen has a twelve month low of $110.04 and a twelve month high of $213.50. The firm has a market cap of $19.35 billion, a price-to-earnings ratio of 12.61, a PEG ratio of 1.78 and a beta of 0.13.

Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.93 by $1.54. Biogen had a return on equity of 13.85% and a net margin of 15.31%. The business had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.32 billion. During the same quarter last year, the firm posted $5.28 earnings per share. The business’s revenue was up 7.3% compared to the same quarter last year.

Institutional Investors Weigh In On Biogen

Institutional investors have recently added to or reduced their stakes in the business. Opal Wealth Advisors LLC acquired a new stake in Biogen in the first quarter worth about $26,000. Vision Financial Markets LLC acquired a new stake in Biogen in the first quarter worth about $27,000. Greykasell Wealth Strategies Inc. purchased a new position in shares of Biogen in the first quarter worth about $27,000. Colonial Trust Co SC raised its stake in shares of Biogen by 9,300.0% in the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 186 shares during the last quarter. Finally, Zions Bancorporation National Association UT purchased a new position in shares of Biogen in the first quarter worth about $29,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insiders Place Their Bets

In other Biogen news, insider Rachid Izzar sold 2,223 shares of the firm’s stock in a transaction dated Tuesday, July 8th. The stock was sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the sale, the insider owned 6,330 shares of the company’s stock, valued at approximately $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.18% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.